Translational and Pharmacogenomics


Take cutting edge genomics research and develop it into services that will both drive translation of biomedical research – particularly relating to the development of new therapeutics and clinical trials; and integrate into clinical practice to provide direct benefit to patients.

Program Co-Leads

Program Summary

Pharmacogenomics studies the genetic causes in differences to drug dosages observed in patient populations, and the ability to understand these differences can help reduce, among other things, adverse drug reactions. The ultimate goal of the Translational and Pharmacogenomics Research Program is to translate research outcomes into clinical practises that improve patient wellbeing through improved accuracy and reduced cost and time in diagnosis; clinical data available to inform treatment selection and predict treatment response; and patient identification and/or stratification to improve clinical trial outcomes.

This Program will build on the existing state of the art translational genomics services and ongoing research in translational genomics. Program members have a major focus on pharmacogenomics in collaboration with industry partners and have years of experience in producing and analysing genomics data that is directly applicable to pharmacogenomics and using this to develop testing services directly within Health Services. These tests have the potential to benefit every patient in the health system.